242 related articles for article (PubMed ID: 8636781)
1. Early lymphopenia after cytotoxic chemotherapy as a risk factor for febrile neutropenia.
Blay JY; Chauvin F; Le Cesne A; Anglaret B; Bouhour D; Lasset C; Freyer G; Philip T; Biron P
J Clin Oncol; 1996 Feb; 14(2):636-43. PubMed ID: 8636781
[TBL] [Abstract][Full Text] [Related]
2. Early lymphopenia as a risk factor for chemotherapy-induced febrile neutropenia.
Choi CW; Sung HJ; Park KH; Yoon SY; Kim SJ; Oh SC; Seo JH; Kim BS; Shin SW; Kim YH; Kim JS
Am J Hematol; 2003 Aug; 73(4):263-6. PubMed ID: 12879430
[TBL] [Abstract][Full Text] [Related]
3. Baseline and early lymphopenia predict for the risk of febrile neutropenia after chemotherapy.
Ray-Coquard I; Borg C; Bachelot T; Sebban C; Philip I; Clapisson G; Le Cesne A; Biron P; Chauvin F; Blay JY;
Br J Cancer; 2003 Jan; 88(2):181-6. PubMed ID: 12610500
[TBL] [Abstract][Full Text] [Related]
4. A predictive model for life-threatening neutropenia and febrile neutropenia after the first course of CHOP chemotherapy in patients with aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Sutheesophon J; Sutcharitchan P; Swasdikul D
Leuk Lymphoma; 2000 Apr; 37(3-4):351-60. PubMed ID: 10752986
[TBL] [Abstract][Full Text] [Related]
5. Identification of patients at risk for early death after conventional chemotherapy in solid tumours and lymphomas.
Ray-Coquard I; Ghesquière H; Bachelot T; Borg C; Biron P; Sebban C; LeCesne A; Chauvin F; Blay JY;
Br J Cancer; 2001 Sep; 85(6):816-22. PubMed ID: 11556830
[TBL] [Abstract][Full Text] [Related]
6. The use of chemotherapy regimens carrying a moderate or high risk of febrile neutropenia and the corresponding management of febrile neutropenia: an expert survey in breast cancer and non-Hodgkin's lymphoma.
Gerlier L; Lamotte M; Awada A; Bosly A; Bries G; Cocquyt V; Focan C; Henry S; Lalami Y; Machiels JP; Mebis J; Straetmans N; Verhoeven D; Somers L
BMC Cancer; 2010 Nov; 10():642. PubMed ID: 21092320
[TBL] [Abstract][Full Text] [Related]
7. Impact of age group on febrile neutropenia risk assessment and management in patients with diffuse large B-cell lymphoma treated with R-CHOP regimens.
Lugtenburg P; Silvestre AS; Rossi FG; Noens L; Krall W; Bendall K; Szabo Z; Jaeger U
Clin Lymphoma Myeloma Leuk; 2012 Oct; 12(5):297-305. PubMed ID: 23040435
[TBL] [Abstract][Full Text] [Related]
8. CD4 lymphopenia as a risk factor for febrile neutropenia and early death after cytotoxic chemotherapy in adult patients with cancer.
Borg C; Ray-Coquard I; Philip I; Clapisson G; Bendriss-Vermare N; Menetrier-Caux C; Sebban C; Biron P; Blay JY
Cancer; 2004 Dec; 101(11):2675-80. PubMed ID: 15503313
[TBL] [Abstract][Full Text] [Related]
9. Risk model for severe anemia requiring red blood cell transfusion after cytotoxic conventional chemotherapy regimens. The Elypse 1 Study Group.
Ray-Coquard I; Le Cesne A; Rubio MT; Mermet J; Maugard C; Ravaud A; Chevreau C; Sebban C; Bachelot T; Biron P; Blay JY
J Clin Oncol; 1999 Sep; 17(9):2840-6. PubMed ID: 10561360
[TBL] [Abstract][Full Text] [Related]
10. Which one is a risk factor for chemotherapy-induced febrile neutropenia in childhood solid tumors: early lymphopenia or monocytopenia?
Oguz A; Karadeniz C; Ckitak EC; Cil V
Pediatr Hematol Oncol; 2006 Mar; 23(2):143-51. PubMed ID: 16651243
[TBL] [Abstract][Full Text] [Related]
11. A risk model for thrombocytopenia requiring platelet transfusion after cytotoxic chemotherapy.
Blay JY; Le Cesne A; Mermet C; Maugard C; Ravaud A; Chevreau C; Sebban C; Guastalla J; Biron P; Ray-Coquard I
Blood; 1998 Jul; 92(2):405-10. PubMed ID: 9657738
[TBL] [Abstract][Full Text] [Related]
12. [Impact of early lymphopenia on the risk of febrile neutropenia and hematological toxicity].
Ben Nasr S; Zriba S; Kacem K; Yahyaoui Y; El Benna H; Mansouri R; Ben Lakhal R; Meddeb B
Tunis Med; 2015 May; 93(5):283-6. PubMed ID: 26578043
[TBL] [Abstract][Full Text] [Related]
13. Risk and timing of hospitalization for febrile neutropenia in patients receiving CHOP, CHOP-R, or CNOP chemotherapy for intermediate-grade non-Hodgkin lymphoma.
Lyman GH; Delgado DJ
Cancer; 2003 Dec; 98(11):2402-9. PubMed ID: 14635075
[TBL] [Abstract][Full Text] [Related]
14. Patterns of chemotherapy administration in patients with intermediate-grade non-Hodgkin's lymphoma.
Picozzi VJ; Pohlman BL; Morrison VA; Lawless GD; Lee MW; Kerr RO; Ford JM; Delgado DJ; Fridman M; Carter WB
Oncology (Williston Park); 2001 Oct; 15(10):1296-306; discussion 1310-1, 1314. PubMed ID: 11702959
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of febrile neutropenia occurrence in patients with non-Hodgkin lymphoma: data from the INC-EU Prospective Observational European Neutropenia Study.
Pettengell R; Bosly A; Szucs TD; Jackisch C; Leonard R; Paridaens R; Constenla M; Schwenkglenks M;
Br J Haematol; 2009 Mar; 144(5):677-85. PubMed ID: 19055662
[TBL] [Abstract][Full Text] [Related]
16. Elderly patients with aggressive non-Hodgkin's lymphoma treated with CHOP chemotherapy plus granulocyte-macrophage colony-stimulating factor: identification of two age subgroups with differing hematologic toxicity.
Gómez H; Mas L; Casanova L; Pen DL; Santillana S; Valdivia S; Otero J; Rodriguez W; Carracedo C; Vallejos C
J Clin Oncol; 1998 Jul; 16(7):2352-8. PubMed ID: 9667250
[TBL] [Abstract][Full Text] [Related]
17. Neutropenia occurrence and predictors of reduced chemotherapy delivery: results from the INC-EU prospective observational European neutropenia study.
Pettengell R; Schwenkglenks M; Leonard R; Bosly A; Paridaens R; Constenla M; Szucs TD; Jackisch C;
Support Care Cancer; 2008 Nov; 16(11):1299-309. PubMed ID: 18351398
[TBL] [Abstract][Full Text] [Related]
18. Prevention of chemotherapy-induced febrile neutropenia by prophylactic antibiotics plus or minus granulocyte colony-stimulating factor in small-cell lung cancer: a Dutch Randomized Phase III Study.
Timmer-Bonte JN; de Boo TM; Smit HJ; Biesma B; Wilschut FA; Cheragwandi SA; Termeer A; Hensing CA; Akkermans J; Adang EM; Bootsma GP; Tjan-Heijnen VC
J Clin Oncol; 2005 Nov; 23(31):7974-84. PubMed ID: 16258098
[TBL] [Abstract][Full Text] [Related]
19. Intensive sequential chemotherapy with repeated blood stem-cell support for untreated poor-prognosis non-Hodgkin's lymphoma.
Stoppa AM; Bouabdallah R; Chabannon C; Novakovitch G; Vey N; Camerlo J; Blaise D; Xerri L; Resbeut M; Di Stefano D; Bardou VJ; Gastaut JA; Maraninchi D
J Clin Oncol; 1997 May; 15(5):1722-9. PubMed ID: 9164178
[TBL] [Abstract][Full Text] [Related]
20. A randomized, placebo-controlled phase ii study evaluating the reduction of neutropenia and febrile neutropenia in patients with colorectal cancer receiving pegfilgrastim with every-2-week chemotherapy.
Hecht JR; Pillai M; Gollard R; Heim W; Swan F; Patel R; Dreiling L; Mo M; Malik I
Clin Colorectal Cancer; 2010 Apr; 9(2):95-101. PubMed ID: 20378503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
